Form 4: Stoke Therapeutics' Chief Medical Officer, Barry Ticho, Executes Stock Option and Sells Shares

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 1, 2024, Barry Ticho, the Chief Medical Officer of Stoke Therapeutics, exercised stock options to acquire 5,504 shares of common stock at a price of $0.60 per share.
• Simultaneously, Ticho sold 10,000 shares of common stock at a weighted average price of $7.7469 per share, with individual sales ranging from $7.50 to $7.93.
• Following these transactions, Ticho directly owns 2,485 shares of common stock and holds options for 80,442 shares.
• The stock sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 14, 2023.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information. The filing itself doesn't necessarily indicate a positive or negative outlook for the company.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates